Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/v12101178 http://scihub22266oqcxt.onion/10.3390/v12101178 33080984!7589631!33080984     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Viruses 2020 ; 12 (10): ä Nephropedia Template TP {{tp|p=33080984|t=2020. Identification and Tracking of Antiviral Drug Combinations |pdf=|usr=}}{{33080984}} gab.com Text Identification and Tracking of Antiviral Drug Combinations JO: Viruses http://www.kidney.de/pget.php?&tw=1&pmid=33080984 #FOAvip Combination therapies have become a standard for the treatment for HIV and hepatitis C virus (HCV) infections. They are advantageous over monotherapies due to better efficacy, reduced toxicity, as well as the ability to prevent the development of resistant viral strains and to treat viral co-infections. Here, we identify new synergistic combinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), echovirus 1 (EV1), hepatitis C virus (HCV) and human immunodeficiency virus 1 (HIV-1) in vitro. We observed synergistic activity of nelfinavir with convalescent serum and with purified neutralizing antibody 23G7 against SARS-CoV-2 in human lung epithelial Calu-3 cells. We also demonstrated synergistic activity of nelfinavir with EIDD-2801 or remdesivir in Calu-3 cells. In addition, we showed synergistic activity of vemurafenib with emetine, homoharringtonine, anisomycin, or cycloheximide against EV1 infection in human lung epithelial A549 cells. We also found that combinations of sofosbuvir with brequinar or niclosamide are synergistic against HCV infection in hepatocyte-derived Huh-7.5 cells, and that combinations of monensin with lamivudine or tenofovir are synergistic against HIV-1 infection in human cervical TZM-bl cells. These results indicate that synergy is achieved when a virus-directed antiviral is combined with another virus- or host-directed agent. Finally, we present an online resource that summarizes novel and known antiviral drug combinations and their developmental status. Twit Text FOAVip Identification and Tracking of Antiviral Drug Combinations ????Viruses http://www.kidney.de/pget.php?&tw=1&pmid=33080984 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33080984 #FOAvip English Wikipedia <ref>{{Cite pmid|33080984}}</ref> Identification and Tracking of Antiviral Drug Combinations #MMPMID33080984 Ianevski A; Yao R; Biza S; Zusinaite E; Mannik A; Kivi G; Planken A; Kurg K; Tombak EM; Ustav M Jr; Shtaida N; Kulesskiy E; Jo E; Yang J; Lysvand H; Loseth K; Oksenych V; Aas PA; Tenson T; Vitkauskiene A; Windisch MP; Fenstad MH; Nordbo SA; Ustav M; Bjoras M; Kainov DE Viruses 2020[Oct]; 12 (10): ä PMID33080984show ga Combination therapies have become a standard for the treatment for HIV and hepatitis C virus (HCV) infections. They are advantageous over monotherapies due to better efficacy, reduced toxicity, as well as the ability to prevent the development of resistant viral strains and to treat viral co-infections. Here, we identify new synergistic combinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), echovirus 1 (EV1), hepatitis C virus (HCV) and human immunodeficiency virus 1 (HIV-1) in vitro. We observed synergistic activity of nelfinavir with convalescent serum and with purified neutralizing antibody 23G7 against SARS-CoV-2 in human lung epithelial Calu-3 cells. We also demonstrated synergistic activity of nelfinavir with EIDD-2801 or remdesivir in Calu-3 cells. In addition, we showed synergistic activity of vemurafenib with emetine, homoharringtonine, anisomycin, or cycloheximide against EV1 infection in human lung epithelial A549 cells. We also found that combinations of sofosbuvir with brequinar or niclosamide are synergistic against HCV infection in hepatocyte-derived Huh-7.5 cells, and that combinations of monensin with lamivudine or tenofovir are synergistic against HIV-1 infection in human cervical TZM-bl cells. These results indicate that synergy is achieved when a virus-directed antiviral is combined with another virus- or host-directed agent. Finally, we present an online resource that summarizes novel and known antiviral drug combinations and their developmental status. |A549 Cells[MESH] |Antibodies, Neutralizing/pharmacology/therapeutic use[MESH] |Antineoplastic Agents/pharmacology[MESH] |Antiviral Agents/*administration & dosage/pharmacology[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Cell Line[MESH] |Coronavirus Infections/*drug therapy/virology[MESH] |Databases, Pharmaceutical[MESH] |Drug Combinations[MESH] |Drug Discovery[MESH] |Drug Synergism[MESH] |Enterovirus B, Human/drug effects[MESH] |HIV-1/drug effects[MESH] |Hepacivirus/drug effects[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/virology[MESH]Identification and Tracking of Antiviral Drug Combinations (epmc).pdf DeepDyve Pubget Overpricing